Search

Your search keyword '"Yasuhiro Gon"' showing total 4 results
Start Over Author "Yasuhiro Gon" Journal bmj open respiratory research
4 results on '"Yasuhiro Gon"'

1. One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies

Author

Huib A M Kerstjens, Motoi Hosoe, Yasuhiro Gon, Kenneth Chapman, Ana-Maria Tanase, Richard van Zyl-Smit, Jorge Maspero, Abhijit Pethe, Xu Shu, and Peter D’Andrea

Subjects
Medicine, Diseases of the respiratory system, RC705-779
Abstract

Background Despite currently available standard-of-care inhaled corticosteroid (ICS)/long-acting β2-agonist therapies, a substantial proportion of patients with asthma remain inadequately controlled. This pooled analysis evaluated efficacy and safety of mometasone furoate/indacaterol acetate (MF/IND) versus fluticasone propionate/salmeterol xinafoate (FLU/SAL) in patients with inadequately controlled asthma.Methods This analysis included patients from PALLADIUM (NCT02554786) and IRIDIUM (NCT02571777) studies who received high-dose MF/IND (320/150 µg) or medium-dose MF/IND (160/150 µg) one time a day or high-dose FLU/SAL (500/50 µg) two times a day for 52 weeks. Reduction in asthma exacerbations, improvement in lung function, asthma control, and safety were evaluated for 52 weeks.Results In total, 3154 patients (high-dose MF/IND, n=1054; medium-dose MF/IND, n=1044; high-dose FLU/SAL, n=1056) were included. High-dose MF/IND showed 26%, 22% and 19% reductions in rate of severe, moderate or severe, and all (mild, moderate and severe) exacerbations versus high-dose FLU/SAL, respectively, over 52 weeks (all, p

Published
2021
Full Text
View/download PDF

2. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population

Author

Ivan Nikolaev, Hajime Yoshisue, Tsuyoshi Ishii, Hironori Sagara, Nathalie Barbier, Motoi Hosoe, and Yasuhiro Gon

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Population, Mometasone furoate, Quinolones, Iridium, Gastroenterology, Fluticasone propionate, Diseases of the respiratory system, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Post-hoc analysis, Humans, Medicine, Glycopyrronium bromide, 030212 general & internal medicine, education, Asthma, education.field_of_study, RC705-779, business.industry, Nebulizers and Vaporizers, Inhaler, biochemical phenomena, metabolism, and nutrition, medicine.disease, Glycopyrrolate, Drug Combinations, 030228 respiratory system, Indans, Indacaterol, business, Mometasone Furoate, medicine.drug
Abstract

Background and objectiveThe 52-week IRIDIUM study demonstrated the efficacy of indacaterol acetate/glycopyrronium bromide/mometasone furoate (IND/GLY/MF) versus IND/MF and salmeterol xinafoate/fluticasone propionate (SAL/FLU) in patients with symptomatic asthma, despite long-acting β2-agonist/inhaled corticosteroids (LABA/ICS) medium-dose or high-dose, predicted forced expiratory volume in 1 s (FEV1) MethodsThis post hoc analysis evaluated improvements in lung function, asthma control and reduction in asthma exacerbations with IND/GLY/MF medium- (150/50/80 µg) and high-dose (150/50/160 µg) versus IND/MF medium- (150/160 µg) and high-dose (150/320 µg), all one time per day and SAL/FLU high-dose (50/500 µg) two times per day, in Asian patients from the IRIDIUM study.ResultsIn total, 258 patients (IND/GLY/MF medium-dose, 52; IND/GLY/MF high-dose, 52; IND/MF medium-dose, 51; IND/MF high-dose, 51; SAL/FLU high-dose, 52) were included. IND/GLY/MF medium- and high-dose showed greater improvement in trough FEV1 at week 26 versus respective doses of IND/MF (Δ, 100 mL and 101 mL; both pConclusionOne time per day, single-inhaler IND/GLY/MF improved lung function, reduced asthma exacerbations and provided comparable asthma control versus IND/MF and SAL/FLU in Asian patients with inadequately controlled asthma despite LABA/ICS. The results of this analysis were consistent with the overall population in the IRIDIUM study.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results